Tags: Drug.

Ticagrelor (trade name Brilinta in the US Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3 2010. The drug was approved by the US Food and Drug Administration on July 20 2011.Ticagrelor is an antagonist of the P2Y12 receptor.

Ticagrelor3.png
ATC prefix
B01
ATC suffix
AC24
Bioavailability
36.0
CAS number
274693-27-5
FDA UNII code
GLH0314RVC
IUPAC name
(1S2S3R5S)-3-[7-[(1R2S)-2-(34-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[123]triazolo[45-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-12-diol
PubChem
9871419

Loading...

This page contains content from the copyrighted Wikipedia article "Ticagrelor"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.